Related Experiment Video
Updated: Mar 8, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells
James R Bowen1,2, Kendra M Quicke1,2, Mohan S Maddur2,3
1Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Abstract:
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that is causally linked to severe neonatal birth defects, including microcephaly, and is associated with Guillain-Barre syndrome in adults. Dendritic cells (DCs) are an important cell type during infection by multiple mosquito-borne flaviviruses, including dengue virus, West Nile virus, Japanese encephalitis virus, and yellow fever virus. Despite this, the interplay between ZIKV and DCs remains poorly defined. Here, we found human DCs supported productive infection by a contemporary Puerto Rican isolate with considerable variability in viral replication, but not viral binding, between DCs from different donors. Historic isolates from Africa and Asia also infected DCs with distinct viral replication kinetics between strains. African lineage viruses displayed more rapid replication kinetics and infection magnitude as compared to Asian lineage viruses, and uniquely induced cell death. Infection of DCs with both contemporary and historic ZIKV isolates led to minimal up-regulation of T cell co-stimulatory and MHC molecules, along with limited secretion of inflammatory cytokines. Inhibition of type I interferon (IFN) protein translation was observed during ZIKV infection, despite strong induction at the RNA transcript level and up-regulation of other host antiviral proteins. Treatment of human DCs with RIG-I agonist potently restricted ZIKV replication, while type I IFN had only modest effects. Mechanistically, we found all strains of ZIKV antagonized type I IFN-mediated phosphorylation of STAT1 and STAT2. Combined, our findings show that ZIKV subverts DC immunogenicity during infection, in part through evasion of type I IFN responses, but that the RLR signaling pathway is still capable of inducing an antiviral state, and therefore may serve as an antiviral therapeutic target.
Insights
Zika virus (ZIKV) infects human dendritic cells (DCs), evading immune responses by inhibiting type I interferon. Targeting the RIG-I pathway shows promise for controlling ZIKV replication in DCs.
Area of Science:
- Virology
- Immunology
- Cell Biology
Background:
- Zika virus (ZIKV) causes severe birth defects and neurological disorders.
- Dendritic cells (DCs) are crucial in flavivirus infections, but ZIKV's interaction with DCs is unclear.
- Understanding ZIKV-DC interplay is vital for developing antiviral strategies.
Purpose of the Study:
- To investigate the interaction between Zika virus and human dendritic cells.
- To determine how ZIKV affects DC function and immune signaling.
- To identify potential therapeutic targets for ZIKV infection.
Main Methods:
- Infection of human dendritic cells with contemporary and historic ZIKV isolates.
- Analysis of viral replication, DC activation markers, cytokine secretion, and type I interferon response.
- Assessment of STAT1/STAT2 phosphorylation and RIG-I agonist/type I interferon treatment effects.
Main Results:
- Human DCs supported productive ZIKV infection with variable replication kinetics between donors and strains.
- ZIKV infection led to minimal DC activation and cytokine secretion, and inhibited type I interferon protein translation.
- ZIKV antagonized type I interferon signaling, but RIG-I agonist treatment potently restricted viral replication.
Conclusions:
- ZIKV subverts DC immunogenicity by evading type I interferon responses.
- The RIG-I signaling pathway remains capable of inducing an antiviral state against ZIKV.
- Targeting the RIG-I pathway presents a potential therapeutic strategy for ZIKV infection.

